In order to evaluate the possibility to use dual PDK1/Aurora kinase A inhibitors as potential in vivo therapeutics, we performed a xenograft experiment using HPAF-II human pancreatic cancer cell line. Here, AURKA is linked to pancreatic neoplasm.